LIVE: Reuters Newsmaker with Lars Fruergaard Jørgensen, CEO of Novo Nordisk

preview_player
Показать описание
Novo Nordisk is the first drugmaker to introduce a highly effective weight-loss drug, Wegovy, at a time of record obesity rates.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, discusses with Reuters Breakingviews columnist Aimee Donnellan the challenge of rapidly ramping up production of Wegovy to meet soaring demand for the breakthrough drug.
 
#LarsFruergaardJørgensen #NovoNordisk #Wegovy AimeeDonnellan #ReutersNewsmaker #Reuters #Live #News #business #finance
  1. Reuters
Рекомендации по теме
LIVE: Reuters Newsmaker 0:46:07

LIVE: Reuters Newsmaker with Lars Fruergaard Jørgensen, CEO of Novo Nordisk

Obesity drug Wegovy 0:01:25

Obesity drug Wegovy is coming to more countries

Three US Marines 0:00:37

Three US Marines die in Australia aircraft crash

Novo Nordisk extends 0:01:03

Novo Nordisk extends curbs on Wegovy

Novo Nordisk Raises 0:07:03

Novo Nordisk Raises Forecasts on New Obesity Drug

Novo Nordisk launches 0:01:22

Novo Nordisk launches Wegovy in Britain

Mizuho's Jared Holz 0:03:25

Mizuho's Jared Holz on Novo Nordisk: There's not much upside near-term

Gravitas: Wegovy maker 0:03:33

Gravitas: Wegovy maker beats LVMH as Europe's most valuable firm

Ozempic and Wegovy 0:01:57

Ozempic and Wegovy maker sues over compounded, off-brand versions of drugs used for weight loss

Study shows costly 0:07:06

Study shows costly weight loss drug may also cut risks of heart attacks

New weight loss 0:02:06

New weight loss drug Wegovy, COVID variant causing infections

Weight Loss Drugs 0:00:57

Weight Loss Drugs Help Heart Health?!

Novo Nordisk, Eli 0:01:59

Novo Nordisk, Eli Lilly stocks see boost on obesity drugs

Novo Boosts Profit 0:04:35

Novo Boosts Profit Outlook on Obesity Drug Demand

Drug Solutions | 0:08:37

Drug Solutions | Weight-Loss Drugs: Do They Work? Are They Safe?

The Story of 0:09:59

The Story of GLP-1: Episode 2 - 'If you don't fix this'

Supply Issues Plague 0:01:05

Supply Issues Plague High-Demand Drug Wegovy, Leaving Many Unable To Access It

Ozempic: Anti-obesity drug 0:02:15

Ozempic: Anti-obesity drug offers hope of a cure for heart failure

Weight Loss Wednesday: 0:02:57

Weight Loss Wednesday: Low-cost weight loss drug banned in La.

TIME100 Most Influential 0:03:26

TIME100 Most Influential Companies: Novo Nordisk

Novo Nordisk shares 0:06:35

Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%

U.S. doctors are 0:02:49

U.S. doctors are 'wowed' by Novo Nordisk's weight-loss drug data, analyst says

Why Novo Nordisk’s 0:23:13

Why Novo Nordisk’s Drugs Are Anti-Obesity Game-Changers: CNBC Healthy Returns Summit 2023

Davos 2020: Lars 0:01:41

Davos 2020: Lars Rebien Sørensen